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ABSTRACT
Glioblastoma (GBM) is the most common malignant brain tumor in adults, with 
a median survival of 15 months. These poor clinical outcomes have prompted the 
development of drugs that block neoplastic cancer cell growth; however, non-neoplastic 
cell-derived signals (chemokines and cytokines) in the tumor microenvironment may 
also represent viable treatment targets. One such chemokine, Ccl5, produced by low-
grade tumor-associated microglia, is responsible for maintaining neurofibromatosis 
type 1 (NF1) mouse optic glioma growth in vivo. Since malignant gliomas may achieve 
partial independence from growth regulatory factors produced by non-neoplastic 
cells in the tumor microenvironment by producing the same cytokines secreted 
by the stromal cells in their low-grade counterparts, we tested the hypothesis 
that CCL5/CCL5-receptor signaling in glioblastoma creates an autocrine circuit 
important for high-grade glioma growth. Herein, we demonstrate that increased CCL5 
expression was restricted to both human and mouse mesenchymal GBM (M-GBM), a 
molecular subtype characterized by NF1 loss. We further show that the NF1 protein, 
neurofibromin, negatively regulates Ccl5 expression through suppression of AKT/
mTOR signaling. Consistent with its role as a glioblastoma growth regulator, Ccl5 
knockdown in M-GBM cells reduces M-GBM cell survival in vitro, and increases mouse 
glioblastoma survival in vivo. Finally, we demonstrate that Ccl5 operates through an 
unconventional CCL5 receptor, CD44, to inhibit M-GBM apoptosis. Collectively, these 
findings reveal an NF1-dependent CCL5-mediated pathway that regulates M-GBM 
cell survival, and support the concept that paracrine factors important for low-grade 
glioma growth can be usurped by high-grade tumors to create autocrine regulatory 
circuits that maintain malignant glioma survival.
INTRODUCTION
Malignant gliomas (glioblastoma or GBM) are the 
most common brain tumor in adults, with approximately 
over 13,000 individuals in the United States dying 
from their cancer each year. After initial diagnosis, the 
median survival is only 9 months [1, 2], which improves 
to ~15 months following surgical resection, radiation 
and chemotherapy [3]. In an effort to improve clinical 
outcomes for people with this deadly cancer, numerous 
conventional and biologically-based anti-neoplastic 
treatments have been evaluated that specifically target the 
rapidly dividing cancer cells. Unfortunately, these newer 
therapies have resulted in only modest increases in overall 
survival, highlighting the urgent need to identify more 
effective therapies for these brain malignancies.
Over the past decades, numerous reports 
have described an instructive role for the tumor 
microenvironment in glioma formation and maintenance 
[4]. In this regard, glioblastomas contain a rich non-
neoplastic component, including endothelial cells and 
immune system cells (e.g., microglia and macrophages), 
whose function is dictated by small molecules responsible 
for their recruitment and activation. One class of these 
proteins, chemokines, is critical for microglia and 
macrophage infiltration and activation through the 
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expression of chemokine receptors on their plasma 
membranes. Consistent with an ecosystem paradigm in 
which non-neoplastic cells attracted by cancer cells in turn 
support neoplastic cell growth, inhibition of chemokine 
expression or chemokine receptor function has been shown 
to attenuate both low-grade and high-grade glioma growth 
in numerous experimental preclinical model systems 
in vivo. For example, CCL2 recruits regulatory T cells and 
myeloid-derived suppressor cells to increase GBM growth 
[5], as well as indirectly increases glioma invasiveness 
by stimulating IL-6 secretion from tumor-associated 
microglia (TAM) [6]. In addition, CXCL12 and its 
receptors CXCR4/CXCR7 function by maintaining GBM 
stem-like cell survival and increasing glioma cell invasion 
[7, 8]. Similarly, colony stimulating factor-1 (CSF-1) 
creates a supportive glioma microenvironment, such that 
silencing CSF-1-receptor signaling on macrophages is 
sufficient to reduce high-grade glioma growth in mice 
[9, 10]. Together, these experimental observations establish 
a fundamental role for chemokines in glioma biology.
In addition to the chemokines mentioned above, we 
have recently discovered that Ccl5 produced by tumor-
associated microglia is a potent paracrine regulator of 
neurofibromatosis type 1 (NF1)-associated murine low-
grade optic glioma growth [11]. In this experimental 
system, Ccl5 was sufficient to stimulate Nf1-deficient 
optic nerve glial cell proliferation in vitro, whereas 
Ccl5 antibody-mediated inhibition attenuated mouse 
optic glioma proliferation in vivo. Interestingly, CCL5 
has recently emerged as a key member of an autocrine 
cytokine circuit critical for KRAS-driven lung cancer 
growth [12]. Since the NF1 protein, neurofibromin, 
functions as a negative regulator of RAS, specifically 
K-RAS in astroglial cells [13, 14], and NF1 mutation/
loss characterizes the mesenchymal GBM (M-GBM) 
molecular subtype [15], we sought to determine whether 
Ccl5 expression creates a unique autocrine circuit for 
mesenchymal glioblastoma growth.
In this report, we describe for the first time, that 
increased CCL5 expression is enriched in both human and 
mouse M-GBM with NF1 loss. Leveraging Nf1-deficient 
murine M-GBM models, we further demonstrate that Ccl5 
shRNA-mediated knockdown increases glioblastoma cell 
apoptosis in vitro, as well as extends mouse glioblastoma 
survival in vivo. Moreover, neurofibromin negatively 
regulates Ccl5 expression through RAS/AKT/mTOR 
pathway activation. Lastly, Ccl5 produced by the M-GBM 
cells acts in a cell autonomous fashion to increase 
M-GBM cell survival using a non-conventional CCL5 
receptor, CD44, to suppress programmed cell death. 
Collectively, these findings broaden the concept that 
growth regulatory factors produced by non-neoplastic 
cells in the low-grade glioma microenvironment are 
employed to establish autocrine circuits in high-grade 
gliomas, thus facilitating a state of relative stromal 
independence. 
RESULTS 
Ccl5 functions in a cell-autonomous fashion to 
increase M-GBM survival
Based on our previous studies examining CCL5 
expression and function in low-grade glioma, we first 
sought to determine whether CCL5 expression was higher 
in human GBM tumors relative to non-neoplastic brain. 
Using the GSE16011 [16] dataset, for which normal brain 
was available for comparison, CCL5 mRNA levels were 
higher in GBM samples relative to their non-neoplastic 
counterpart (Figure 1A). We next analyzed CCL5 mRNA 
expression in the four GBM molecular subtypes using data 
from the Cancer Genome Atlas (TCGA, provisional), and 
found that mesenchymal GBM (M-GBM) exhibited the 
highest levels of CCL5 mRNA expression, while proneural 
GBM (PN-GBM) expressed the lowest (Figure 1B).
This relative enrichment of CCL5 expression in 
the mesenchymal subtype, which frequently exhibits 
loss of function mutations in the NF1 tumor suppressor 
gene [15], prompted us to focus on murine models 
characterized by Nf1 loss. Using two representative mouse 
M-GBM cell lines (1861 and 4622), which lack Nf1 and 
Tp53 expression [17], and two representative mouse 
proneural GBM cell lines ((2)61 and (5)54), which retain 
neurofibromin expression (Figure 1C) [18], we found that 
Ccl5 levels were elevated in the culture medium of mouse 
M-GBM cells relative to PN-GBM cells, as well as to 
wild-type primary mouse astrocytes (Figure 1D).
To determine whether M-GBM cell growth was 
dependent on Ccl5 expression, 1861 (M-GBM) cells were 
grown in the presence of mouse Ccl5 (mCcl5). mCcl5 
treatment increased cell growth, as revealed by ~14% 
increase in BrdU incorporation relative to the vehicle 
treatment (Figure 2A). Next, we reduced Ccl5 levels in 
1861 cells by shRNA-mediated knockdown (KD). Using 
two independent constructs (shCcl5-1 and shCcl5-2), Ccl5 
protein levels were reduced to ~20% of control levels (LacZ 
shRNA; Figure 2B), resulting in reduction in cell number 
(Figure 2C) and cell growth (BrdU incorporation; Figure 2D) 
as a consequence of increased apoptosis (increased 
cleaved caspase-3 expression and %TUNEL+ cells; 
Figure 2E–2G). Similar results were obtained using another 
M-GBM cell line (4622; Supplementary Figure 1A–1E). 
Importantly, treating PN-GBM cells with mCcl5 did not 
affect cell growth, suggesting that Ccl5 is not a regulator for 
PN-GBM growth (Supplementary Figure 1F). 
Based on these in vitro results, we also sought to 
determine whether Ccl5 is required for M-GBM growth 
in vivo. Control (shLacZ) and Ccl5 KD (shCcl5-1 and 
shCcl5-2) 1861 cells were stereotactically implanted 
into the striata of 4-week-old wild-type C57BL/6 mice. 
Both Ccl5 KD groups demonstrated reduced Ccl5 levels 
(Figure 3A), reduced cell proliferation (%Ki67+ cells, 
Figure 3B, 3C) at time of death, as well as longer survival 
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relative to the control (shLacZ) group (Figure 3D). In 
addition, tumor implants dissected at 6-weeks post-
implantation demonstrated reduced Ccl5 levels, increased 
apoptosis (cleaved caspase-3 expression), and reduced cell 
proliferation (PCNA expression) in the Ccl5 KD groups 
(Supplementary Figure 2).
Given the role of Ccl5 as a chemokine, it may 
recruit monocytes to the implantation site to facilitate 
tumor growth; however, we found no change in the 
number of recruited monocytes or chemokine expression 
within the tumor between the control and Ccl5 KD groups 
(data not shown). In addition, we sought to determine 
whether Ccl5 produced by non-neoplastic cells contributes 
to M-GBM tumor growth by comparing M-GBM cell 
growth in wild-type versus Ccl5−/− mouse striata. Mouse 
survival and tumor proliferation were similar between 
the two groups, arguing against a major stromal source 
for Ccl5 in mediating the observed M-GBM survival 
effects (Supplementary Figure 3). Collectively, these 
observations demonstrate that Ccl5 positively regulates 
M-GBM growth in vivo and in vitro through an autocrine 
stimulatory mechanism.
Neurofibromin negatively regulates Ccl5 
expression through suppression of AKT/mTOR 
pathway activation
Since increased CCL5 expression predominates in 
the M-GBM molecular subtype and mouse Nf1-deficient 
GBM cells exhibit reduced growth following Ccl5 KD, we 
tested the hypothesis that the NF1 protein (neurofibromin) 
function is responsible for regulating Ccl5 expression. 
Using primary brainstem astrocytes from postnatal 
day 1 mice (Nf1flox/flox astrocytes infected with Ad5-LacZ 
virus, Nf1+/+; Nf1flox/flox astrocytes infected with Ad5-
Cre virus, Nf1−/−) (Supplementary Figure 4A), Ccl5 
levels in the medium were increased in Nf1−/− astrocytes 
relative to wild-type (Nf1+/+) controls (Figure 4A). 
To establish causality, we re-introduced the functional 
domain of neurofibromin (NF1-RAS GTPase-activating 
protein regulatory domain [NF1-GRD; GRD-WT]; 
Supplementary Figure 4B). A mutant NF1-GRD construct 
(NF1-GRDR1276P; GRD-Mut) defective at suppressing RAS 
activity was used as a control for RAS-GAP activity [19]. 
Expression of WT, but not mutant, NF1-GRD reduced 
Figure 1: M-GBM express high levels of CCL5. (A) Human GBM samples (GSE16011 [16]) have elevated CCL5 mRNA levels 
relative to normal brain (NB). **p = 0.0023. (B) CCL5 mRNA expression (Log2 Z-score) in TCGA GBM (provisional) samples segregated by 
molecular subgroup reveals that mesenchymal and proneural GBM express the highest and lowest CCL5 levels, respectively. **p = 0.0095; 
****p < 0.0001. n = 106, 55, 102, and 96 for the mesenchymal, neural, classical and proneural molecular GBM subgroups, respectively. (C) 
M-GBM cells are neurofibromin deficient, while PN-GBM cells express neurofibromin. (D) Ccl5 ELISA analysis of the culture medium 
reveals higher levels of Ccl5 in M-GBM cells relative to PN-GBM cells and primary astrocytes. ****p < 0.0001. FC, fold change.
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Ccl5 levels in 1861 cells (Figure 4B), demonstrating that 
neurofibromin negatively regulates Ccl5 expression.
Neurofibromin regulates glioma cell growth 
through the AKT/mTOR pathway [20, 21], such that 
Nf1−/− astrocytes exhibit AKT/mTOR hyperactivation 
relative to Nf1+/+ (wild-type) astrocytes (Supplementary 
Figure 4A). Consistent with this neurofibromin regulatory 
function, AKT/mTOR activity in 1861 cells was reduced 
following NF1-GRD expression (Supplementary 
Figure 4C). Moreover, AKT pharmacological inhibition 
(MK2206) of M-GBM cells similarly reduced AKT 
activity (Figure 4C, 4D) and Ccl5 expression (Figure 4E). 
In addition, AKT inhibition in 1861 cells reduced mTOR 
activity (Figure 4F, 4G), and mTOR inhibition using 
rapamycin (Figure 4F, 4G) reduced Ccl5 expression 
(Figure 4H). The concentrations and durations of inhibitor 
treatments were specifically selected so that cell growth was 
not affected (Supplementary Figure 4D), arguing that any 
potential changes in Ccl5 expression were a secondary effect 
of suppressed cell growth. As a complementary approach, 
we employed shRNA knockdown of Raptor, a molecule 
critical for the function of mTOR complex-1 (Figure 4I). 
Similar to rapamycin treatment, Raptor KD reduced Ccl5 
expression (Figure 4J). However, in these experiments, cell 
growth was inhibited following Raptor KD (Supplementary 
Figure 4E), requiring that the amount of Ccl5 present in the 
medium be normalized to the total cell number.
Since MEK/ERK activation is also elevated 
following NF1 loss [22], we analyzed Ccl5 expression 
following PD-0325901 (PD901, MEK inhibitor) treatment. 
In these experiments, MEK inhibition did not change Ccl5 
expression (Supplementary Figure 5). Collectively, these 
experiments establish RAS-GAP/AKT/mTOR signaling 
as the primary mechanism underlying neurofibromin 
regulation of Ccl5 expression.
Ccl5 controls M-GBM survival through CD44
CCL5 functions by binding to G-protein coupled 
receptors, including CCR (C-C chemokine receptor) 1, 
3 and 5. Surprisingly, Ccr1, Ccr3 or Ccr5 mRNA levels 
were nearly undetectable in M-GBM cells (Supplementary 
Figure 6), prompting us to investigate non-conventional 
CCL5 receptors (GPR75, CXCR4 and CD44) as potential 
binding partners [23, 24]. In these experiments, only Cd44 
mRNA was detected in 1861 and 4622 cells (Figure 5A), 
which also observed at the protein level (Figure 5B). 
Importantly, CD44 mRNA expression in human GBM 
subtypes was highest in the mesenchymal group, and was 
lowest in the proneural group (Figure 5C). 
To determine whether CD44 was necessary for 
M-GBM cell survival, we reduced Cd44 expression in 
1861 cells using shRNA. Following Cd44 KD, there 
was increased apoptosis (cleaved caspase-3 expression 
and %TUNEL+ cells) relative to controls (LacZ KD) 
(Figure 5D, 5E). In order to demonstrate that CD44 
functions as the receptor for Ccl5 in 1861 cells, Cd44 
KD cells were treated with mCcl5. Following Cd44 
Figure 2: Ccl5 functions in a cell-autonomous fashion to increase M-GBM cell survival. (A) Increased BrdU incorporation 
was observed in 1861 cells following treatment with mouse Ccl5 (mCcl5). Vehicle was 0.5% BSA in PBS. **p = 0.009. (B) ELISA analysis 
of 1861 cell medium shows that Ccl5 KD (shCcl5-1, shCcl5-2) cells produce less Ccl5 compared to control (shLacZ) cells. ****p < 0.0001. 
FC, fold change. (C) Ccl5 KD cells exhibit reduced cell numbers. *p = 0.0428 (shLacZ vs shCcl5-1), and p = 0.0162 (shLacZ vs shCcl5-2). 
(D) Ccl5 KD cells exhibit reduced cell growth (BrdU incorporation). ****p < 0.0001. (E) Western blotting demonstrates increased cleaved 
caspase-3 (c-caspase-3) expression following Ccl5 KD. (F, G) Ccl5 KD increases the percentage of TUNEL+ cells (green; arrows). DAPI-
stained nuclei (inset) are shown in blue. **p = 0.0039 (shLacZ vs shCcl5-1), and p = 0.0063 (shLacZ vs shCcl5-2). Scale bar, 25 μm. 
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KD, mCcl5 could no longer increase 1861 cell growth 
(Figure 6A). Similarly, Ccl5 KD in Cd44 KD cells 
(Figure 6B) did not change cell growth (Figure 6C), 
establishing that the growth-promoting effects of Ccl5 
require CD44 expression on M-GBM cells. In order to 
test whether other CD44 ligands function in a similar 
fashion as Ccl5, we reduced Cd44 using shRNA in 
Ccl5 KD cells (shCcl5 + shCd44), and compared cell 
proliferation to that observed in Ccl5 KD (shCcl5) and 
control (shLacZ) cells. It should be noted that the shLacZ 
and shCcl5 cells were further infected with virus carrying 
the shLacZ construct as an internal control for a second 
round of viral infection. We observed no further reduction 
of cell proliferation in Ccl5 KD cells following Cd44 
knockdown (Figure 6D–6F), suggesting that this pro-
survival pathway is specific to the interaction between 
Ccl5 and CD44, and is not regulated by other CD44 
ligands. Taken together, these data support a model in 
which Nf1 loss in M-GBM cells leads to hyperactivation 
of the AKT/mTOR pathway, which positively regulates 
Ccl5 expression and increases M-GBM cell survival 
through CD44 signaling (Figure 6G). 
Figure 3: Ccl5 knockdown reduces M-GBM growth and prolongs mouse survival in vivo. Ccl5 KD (shCcl5-1, shCcl5-2) and 
control (shLacZ) 1861 cells were implanted into the striata of C57BL/6 mice. Ccl5 KD groups have fewer Ccl5+ (red; A), Ki67+ cells (B, C, 
arrow) relative to controls. *p = 0.0145; **p = 0.0014. Scale bars, 10 μm (A) and 50 μm (B). (D) Kaplan-Meier survival curves demonstrate that 
the Ccl5 KD groups have prolonged survival relative to controls. Each group contains 9–10 mice. *p = 0.0117; **p = 0.0037 (Log-rank test).
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DISCUSSION
Chemokines were originally described as key 
signaling molecules in cancer biology by virtue of 
their ability to recruit stromal cells (e.g., macrophages, 
endothelial cells) to the developing tumor [25, 26]. 
While this is one important function for these immune 
modulatory proteins, emerging evidence suggests that 
chemokines and cytokines may create autocrine growth 
regulatory circuits that facilitate tumor expansion. In this 
regard, CXCR2 signaling has been shown to regulate 
KRAS-induced pancreatic cancer growth [27], whereas 
IL-8 serves as an autocrine growth factor for malignant 
mesothelioma maintenance [28]. In the context of 
glioma, CXCL12/CXCL12-receptor (CXCR4/CXCR7) 
autoregulatory signaling has been demonstrated to be 
important for glioblastoma survival [8, 29, 30] and 
angiogenesis [31], while CX3CL1/CX3CR1 axis signaling 
in glioma cells controls glioma cell invasion [32]. 
The emergence of such autoregulatory chemokine/
chemokine receptor loops relevant to glioma growth 
prompted us to examine a recently-identified paracrine 
signal (CCL5), produced by low-grade glioma-associated 
microglia [11], as a potential autocrine signaling molecule 
in high-grade glioma. While low-grade gliomas are 
dependent on growth-facilitatory signals from the tumor 
microenvironment, we hypothesize that their malignant 
counterparts achieve partial stromal independence by 
producing the very growth factors elaborated by non-
neoplastic cells in low-grade gliomas. In this study, we 
demonstrate that M-GBM cells express high levels of 
CCL5 that provides an auto-stimulatory signal to increase 
cell survival. Similarly, in other studies, M-GBM cells 
express high levels of CXCL12, which forms another 
autoregulatory loop with its receptor CXCR4/CXCR7, 
to increase GBM cell proliferation [8, 29, 30]. In NF1-
associated low-grade gliomas, CXCL12 also serves as a 
paracrine factor that drives the growth of neoplastic Nf1−/− 
astrocytes [33]. These findings support the idea that high-
grade glioma cells achieve certain degrees of stromal 
independence by producing growth factors previously 
provided by non-neoplastic stromal cells in the low-grade 
glioma tumor microenvironment. 
CCL5 is a potent chemokine operative in several types 
of cancers, including lymphoma, melanoma, prostate cancer 
and breast cancer [34]. However, while CCL5 function in 
glioma has not been fully elucidated, several reports have 
suggested that it might be an important chemokine in this 
setting. First, one of the main CCL5 receptors, CCR5, is 
expressed in U87 and U251 glioblastoma cell lines, such 
that its knockdown inhibits U87 growth in nude mice [35]. 
Second, CCL5 mRNA and protein expression are elevated 
in both tumor tissue and serum from patients with high-
grade glioma [36]. Lastly, CCL5 is produced by microglia 
Figure 4: Ccl5 expression in M-GBM cells is regulated by neurofibromin-mediated AKT/mTOR pathway suppression. 
(A) ELISA analysis demonstrates greater Ccl5 levels in the medium from Nf1−/− astrocytes relative to their wild-type (Nf1+/+) counterparts. 
*p = 0.01. FC, fold change. (B) Wild-type NF1-GRD (GRD-WT) expression in 1861 cells reduced Ccl5 expression relative to the NF1-GRD 
R1276P mutant (GRD-Mut). ****p < 0.0001. (C, D) Treatment of 1861 cells with MK2206 (AKT inhibitor) reduced AKT activity 
(phospho-AKTS473/AKT ratio) compared to DMSO (vehicle control). **p = 0.0012. (E) ELISA reveals reduced Ccl5 expression following 
MK2206 treatment. *p = 0.0258. FC, fold change. (F, G) MK2206 or rapamycin (mTOR inhibitor) treatment reduced mTOR activity 
(phospho-S6S240/S244/S6 ratio). *p = 0.0362 (DMSO vs MK2206) and p = 0.0116 (DMSO vs rapamycin). (H) Rapamycin-treated 1861 cells 
had reduced Ccl5 levels in the medium compared to DMSO controls. *p = 0.0313. FC, fold change. (I) Western blotting demonstrates that 
shRNA-mediated Raptor KD (shRaptor-1 and shRaptor-2) reduced Raptor protein expression in 1861 cells relative to control (shLacZ) 
vector. (J) Raptor KD results in reduced Ccl5 levels in the medium. **p = 0.002 (shLacZ vs shRaptor-1), and p = 0.0034 (shLacZ vs 
shRaptor-2). FC, fold change.
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in the microenvironment of murine Nf1 optic glioma, and 
is increased in low-grade gliomas (pilocytic astrocytoma) 
relative to non-neoplastic tissue [11]. In this latter study, 
CCL5 treatment increased optic nerve glial proliferation 
in vitro, whereas antibody-mediated CCL5 inhibition 
reduced optic glioma growth in vivo.
CCL5 typically functions by binding to its receptors 
CCR1, CCR3 and/or CCR5. Surprisingly these receptors 
were not detectable in M-GBM cells. Instead, M-GBM 
cells express the non-conventional CCL5 receptor, CD44, 
and use this receptor to maintain tumor cell survival. 
CD44 is a cell surface glycoprotein that can function 
as a co-receptor for extracellular matrix components, 
growth factors and chemokines. CD44 plays several 
critical roles in GBM and drives GBM cell invasion, 
proliferation and drug resistance. CD44 expression is 
increased in GBM compared to low-grade gliomas and 
high levels of CD44 are associated with worse survival 
of GBM patients [37]. Inhibiting CD44 function using 
monoclonal antibodies or RNA silencing reduced GBM 
growth in vivo and prolonged mouse survival [38, 39]. The 
interaction between CD44 and its ligands (e.g., hyaluronic 
acid and osteopontin) modulates multiple aspects of 
glioma biology. Activation of CD44 by hyaluronic acid 
was shown to increase glioma cell invasion [40–43]. In 
addition, osteopontin-CD44 interaction induces cleavage 
of the intracellular domain of CD44, increases a stem 
cell phenotype, and increases the growth of PN-GBM 
cells [44]. In this study, we found that the interaction 
between Ccl5 and CD44 enhances cell survival in 
M-GBM cells. This pro-survival effect is specific to Ccl5, 
and does not appear to involve other CD44 ligands, since 
Cd44 knockdown in Ccl5 KD cells does not further reduce 
cell growth. Our study expands our understanding of the 
potential mechanisms by which CD44 regulates GBM 
maintenance.
CCL5 employs CD44 as an alternative receptor 
to facilitate the entry of HIV virus [24], where it forms 
a complex with CD44 and Src kinases to activate ERK 
signaling. In our studies, ERK activity in M-GBM 
cells was not reduced following Ccl5 KD (data not 
shown), suggesting that a distinct signaling pathway is 
activated following Ccl5 binding to CD44 in M-GBM 
cells. Previous studies have demonstrated increased cell 
survival following CD44 activation in several different 
cancers. For example, CD44 protects chronic lymphocytic 
leukemia cells from spontaneous and induced cell death 
by increasing expression of the MCL-1 pro-survival 
Figure 5: CD44 is required for M-GBM cell survival. (A) qPCR analysis of Cd44 mRNA in spleen (positive control), primary 
astrocytes, mesenchymal GBM (M-GBM) and proneural GBM (PN-GBM) cells reveals higher Cd44 mRNA levels in M-GBM cells relative 
to PN-GBM cells and primary astrocytes. ****p < 0.0001. FC, fold change. (B) CD44 protein is detected by Western blot in M-GBM, but 
not in PN-GBM, cells. (C) CD44 mRNA expression (Log2 Z-score) in TCGA GBM (provisional) samples segregated by molecular subgroup 
reveals that mesenchymal and proneural GBM express the highest and lowest CD44 levels, respectively. ****p < 0.0001. (D) Cd44 KD 1861 
cells (shCd44) have increased cleaved caspase-3 (c-caspase-3) expression relative to control (shLacZ) cells. (E) Increased %TUNEL+ cells 
(inset) are observed following Cd44 KD (green; arrows). DAPI-stained nuclei are shown in blue. *p = 0.0288. Scale bar, 25 μm.
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Figure 6: Ccl5 regulates M-GBM survival through CD44. (A) Cd44 KD 1861 cells treated with vehicle (0.5% BSA in PBS) or 
mouse Ccl5 (mCcl5) show no difference in BrdU incorporation. n.s., not significant. (B) ELISA analysis shows that shCd44 + shCcl5 cells 
have reduced levels of secreted Ccl5 relative to controls (shCd44 + shLacZ). ****p < 0.0001. FC, fold change. (C) Ccl5 KD in Cd44 KD 
cells did not change BrdU incorporation. n.s., not significant. (D) ELISA analysis shows that Ccl5 KD cells (shCcl5 + shLacZ and shCcl5 + 
shCd44) have reduced levels of secreted Ccl5 relative to control cells (shLacZ + shLacZ). ****p < 0.0001. ***p = 0.0002. FC, fold change. 
n.d., not detected. (E) Western blotting demonstrates that Cd44 KD cells (shCcl5 + shCd44) have less CD44 protein relative to other cells 
(shLacZ + shLacZ and shCcl5 + shLacZ). (F) Cd44 KD in Ccl5 KD cells did not change BrdU incorporation. n.s., not significant. (G) 
Proposed model for Ccl5 regulation of M-GBM cell survival.
Oncotarget32985www.impactjournals.com/oncotarget
protein [45], while CD44 activation in breast cancer 
cells induces c-Jun mediated survival [46]. It has been 
suggested in GBM that CD44 also inhibits the Hippo-
mediated apoptotic signaling pathway to achieve resistance 
to reactive oxygen species- or cytotoxic agent-induced 
stress [39]. Further work will be required to determine how 
CD44 regulates cell survival in M-GBM cells.
GBM tumors are genetically heterogeneous and 
can be divided into mesenchymal, classical, neural and 
proneural subtypes. Herein, we focused on studying the 
behavior of mesenchymal GBM since Ccl5 has the highest 
expression in this group. One common feature of the 
M-GBM subtype is NF1 loss/mutation, which results in 
impaired neurofibromin RAS suppression. Consistent 
with this observation, we demonstrated that neurofibromin 
directly regulates CCL5 expression through RAS signaling. 
First, we show that ectopic expression of a functional, 
but not mutant, NF1-GAP-related domain reduced Ccl5 
expression. Second, Nf1 loss in primary astrocytes resulted 
in increased Ccl5 expression. Third, pharmacological 
inhibition of RAS downstream effector activation (AKT/
mTOR) suppressed Ccl5 expression in M-GBM cells. 
Collectively, these results elucidate one mechanism by 
which Ccl5 expression is controlled by RAS. 
The Ccl5-mediated autocrine circuit identified in this 
study may not apply to other GBM subtypes, given that 
they do not express high levels of either CCL5 or CD44. 
In fact, we have shown that treating murine PN-GBM cells 
with Ccl5 did not increase cell growth. While multiple 
signaling pathways contribute to GBM tumorigenesis, we 
report one in which a chemokine-driven autocrine pathway 
supports GBM cell survival. The regulation of chemokines 
by oncogenic signaling pathways suggests that other 
brain cancer-associated mutations might similarly 
modulate chemokine production. Further dissection of the 
chemokine/cytokine networks regulated by these tumor 
suppressor/oncogenic pathways might uncover unique 
immune modulatory programs with differential impact 
not only on tumor cell growth, but also on the stromal cell 
types in the tumor microenvironment. 
Lastly, while Ccl5 silencing results in ~20% 
reduction in cell growth in vitro, there was a ~70% 
reduction in tumor cell growth following Ccl5 KD 
in vivo. The greater cell survival benefit in vivo raises 
the possibility that CCL5 may not solely function in 
an autocrine manner, but may also recruit monocytes 
(macrophages/microglia) to the tumor and enhance tumor 
growth in a paracrine manner. However, we found no 
difference in the percent of intratumoral Iba1+ monocytes 
in mice bearing Ccl5 KD versus control (LacZ KD) 
M-GBM cells (data not shown). Since it is possible that 
attenuated Ccl5 expression alters the functional status of 
tumor-associated macrophages/microglia, current studies 
are focused on identifying potential changes in the tumor 
microenvironment conferred by reduced glioblastoma 
tumor cell Ccl5 production in vivo. 
In summary, we demonstrate, for the first time, 
that CCL5 functions in an autocrine growth-promoting 
circuit, and establish a new receptor responsible for CCL5 
function in mesenchymal glioblastoma cells. We further 
show that key oncogenic signaling pathways, like RAS, 
operate to modulate chemokine expression. As such, these 
studies expand the role of chemokines in dictating glioma 
biology, and suggest that paracrine growth regulatory 
signals produced by non-neoplastic cells in the low-grade 
glioma microenvironment may be converted to autocrine 
tumor maintenance circuits in high-grade malignancies 
relevant to mesenchymal glioblastoma survival in vitro 
and in vivo.
MATERIALS AND METHODS 
Human CCL5 and CD44 expression analysis
Expression values for CD44 and CCL5 (Glioblastoma, 
TCGA Provisional, mRNA Expression z-Scores) were 
obtained from the MSKCC computational biology cancer 
genomics portal (http://www.cbioportal.org), which contains 
annotated TCGA data [47, 48]. Tumor subtype classification 
was performed as previously described [15].
Mice
4-week-old male C57BL/6 mice were purchased 
from Taconic, and used in accordance with an approved 
Animal Studies Committee protocol at Washington 
University.
Cell culture 
Mouse mesenchymal glioblastoma cells (1861 and 
4622) were maintained as previously described [49], while 
mouse proneural glioblastoma cells ((2)61 and (5)54)) were 
derived from PDGFB-driven tumor-bearing mice [18] and 
grown in mouse neural stem cell medium (STEMCELL 
Technologies, 05700 and 05701), supplemented with 
20 ng/ml hEGF (Sigma-Aldrich, E9644), 10 ng/ml 
hFGF (R&D systems, 233-FB-025) and 2 μg/ml heparin 
(STEMCELL Technologies, 07980). Wild-type and 
Nf1−/− primary astrocytes were generated and maintained 
as previously described [14, 50, 51]. Before performing 
qPCR, ELISA or Western blotting, all cells were cultured 
under the same condition for at least 24 hours. 
Lentiviral infection
pLKO.1 plasmids with shRNAs targeting LacZ, 
Ccl5 (shCcl5-1 and shCcl5-2), and Cd44 were obtained 
from the Genome Institute at Washington University, while 
shRaptor-1 and shRaptor-2 plasmids were purchased 
(Addgene, 21339 and 21340) (Supplementary Table 1). 
shRNAs were prepared and cells infected as previously 
Oncotarget32986www.impactjournals.com/oncotarget
reported [49]. MSCV-NF1-GRD-WT and mutant control 
constructs [19] were transfected into 1861 cells using 
X-tremeGENE 9 DNA transfection reagents (Roche 
Life Science, XTG9-RO) according the manufacturer’s 
protocol.
Pharmacologic treatments
1861 cells were treated with 0.4 μM ZSTK474 
(Selleckchem, S1072), 1 μM MK2206 (Selleckchem, 
S1078), 5 nM rapamycin (Selleckchem, S1039), 1 nM PD-
0325901 (PD901; Selleckchem, S1036) or DSMO (vehicle 
control, Sigma-Aldrich, D8418) for 4 hours at 37°C. 
BrdU incorporation
Cells were plated in 96-well plates, and treated with 
250 ng/mL mCcl5 (R&D systems, 478-MR-025) or 0.5 % 
BSA in PBS (vehicle control) for 4 hours at 37°C. BrdU was 
added to the cell culture 2 hours before fixing the cells and 
performing the BrdU ELISA assay (Roche Life Science, 
11647229001) according the manufacturer’s protocol.
Terminal deoxynucleotidyl transferase dUTP 
nick end labeling (TUNEL)
Cells maintained in 0.5% fetal bovine serum for 
24 hours were fixed with 4% PFA, and TUNEL+ cells 
detected using the fluorescence-based in situ cell death 
detection kit (Roche Life Science, 11684795910). The 
number of TUNEL+ cells was normalized to the total cell 
number (DAPI+ nuclei) using NIH ImageJ software.
Western blotting
1861 cells expressing shRNAs were maintained in 
0.5% fetal bovine serum for 24 hours prior to lysis and 
Western blotting with appropriate primary antibodies 
(Supplementary Table 2) [14, 52]. Quantification of western 
blots were performed using ImageStudio (LI-COR). AKT 
and S6 activities were quantified as signal intensity of 
phospho-proteins versus signal intensity of total proteins. 
Mouse chemokine enzyme-linked 
immunosorbent assay (ELISA)
Cells were serum starved for 24 hours, and the 
culture medium collected for mouse Ccl5 ELISA 
(R&D systems, MMR00). The amount of secreted Ccl5 
determined by ELISA was normalized to total cell number.
Quantitative real-time PCR
qPCR was performed as described previously [11] 
using validated primers (Supplementary Table 3).
Intracranial injections
5 × 104 1861 cells were implanted into the striatum 
of 4-week-old C57BL/6 mice as previously described 
[49]. Mice were monitored daily, and euthanized when 
moribund. Kaplan-Meier survival curves were generated, 
and differences between control (shLacZ) and Ccl5 KD 
(shCcl5-1 and shCcl5-2) groups analyzed using the Log-
rank test. For mCcl5 ELISA and Western blotting of the 
implant, tissue around the tumor implantation site was 
dissected 6-weeks post-implantation, followed by lysing 
the tissue as described previously [14, 52].
Immunohistochemistry
Implanted mouse brains were fixed at the time 
of death or deemed moribund by the veterinary staff, 
embedded in paraffin and processed as described previously 
[53], followed by performing immunohistochemistry using 
primary and secondary antibodies (Supplementary Table 2). 
Ccl5 signal was amplified using tyramide signal 
amplification as described previously [11]. 
Statistical analyses
Data analysis was performed using Prism GraphPad. 
Unpaired two-tailed Student’s t tests were used to 
determine the difference between two groups. All data 
were presented as mean values with standard error of 
mean (SEM). All in vitro experiments were repeated at 
least three times with similar results.
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